Drug details

Imcivree (setmelanotide injection, for subcutaneous use)

type of Melanocortin Agonists

Imcivree (setmelanotide) is a melanocortin 4 (MC4) receptor agonist indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).

The drug is often used to treat Obesity .

This drug may have the following side effects:

• nausea,
• vomiting,
• diarrhea,
• back pain,
• headache,
• fatigue,
• abdominal pain,
• depression,
• upper respiratory tract infection, and
• injection site reactions,
• skin hyperpigmentation,
• spontaneous penile erection

The following drugs are related to Imcivree, either as a replacement or used together:

• Contrave (naltrexone hcl and bupropion hcl extended-release tablets)
• Saxenda (liraglutide [rdna origin]) injection)
• Xenical (orlistat 120 mg)
• Qsymia (phentermine and topiramate)